-
The prescription rate of testosterone therapy has increased dramatically in the last decade, and primary care practitioners are asked on a daily basis about testosterone supplementation. Ingenious marketing has led many patients — many of whom are older and have risk factors for heart disease — to question if testosterone therapy is right for them.
-
Johnston BC, et al. Comparison of weight loss among named diet programs in overweight and obese adults: A meta-analysis.
-
The probiotic movement is rapidly growing and, although to date no probiotics have been approved by the FDA, they are actively marketed to the public as either foods or dietary supplements. It behooves the primary care physician to be familiar with the science, indications, and appropriate usage of probiotic therapies.
-
Patients with unprovoked venous thromboembolism (VTE) are at high risk of recurrence after discontinuation of vitamin K antagonist (such as warfarin) therapy, with an approximately 10% risk of recurrence within the first year and 5% risk per year thereafter.
-
This 150-day, randomized, double-blind, placebo controlled trial (RCT) with 465 healthy adult volunteers (mean age 37 years old) was designed to examine the effects of probiotics on the incidence of upper respiratory tract infections (URTI).
-
The FDA has approved two drugs for the treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone is an antifibrotic agent and nintedanib is a tyrosine kinase inhibitor. Both products were approved on a fast-track priority review, with orphan status and breakthrough designation. Pirfenidone is marketed by InterMune as Esbriet and nintedanib as Ofev by Boehringer Ingelheim.
-
An objective, laboratory based diagnostic tool for depression would be extremely helpful to primary care physicians. This study using nine biomarkers holds promise that a blood test may be able to identify depressed patients among non-depressed primary care patients
-
-
Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients with Isolated Systolic Hypertension and LVH; Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and Nondiabetic Postmenopausal Women
-
The FDA has approved Ezetimibe, the first drug in a new class of cholesterol-lowering medications.